SCYNEXIS (LTS:0L49) 5-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS 5-Year EBITDA Growth Rate?

SCYNEXIS's EBITDA per Share for the three months ended in Mar. 2024 was $0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of SCYNEXIS was 47.80% per year. The lowest was 2.10% per year. And the median was 29.20% per year.

Competitive Comparison of SCYNEXIS's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SCYNEXIS's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's 5-Year EBITDA Growth Rate falls into.

SCYNEXIS 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

SCYNEXIS (LTS:0L49) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

SCYNEXIS 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS (LTS:0L49) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

SCYX:USA 135A:Germany

Address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548

Website

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines